Chronic kidney disease

Study findings suggest targeted inhibition of APOL1 function can reduce proteinuria.

For patients with recurrent kidney stones, no difference seen in recurrence with hydrochlorothiazide 12.5, 25, 50 mg versus placebo

February 2023 Notable Drug Approvals

Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.

Sparsentan is an endothelin and angiotensin II receptor antagonist.

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted.

If renin-angiotensin system inhibitors are indicated in patients with advanced CKD, they should not be stopped just because of low eGFR, investigators concluded.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.

Danish investigators compared direct oral anticoagulants with vitamin K antagonists in 33,670 patients with atrial fibrillation.

Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.

The application is supported by data from the phase 3 EMPA-KIDNEY trial, which enrolled more than 6600 adults with CKD at risk of kidney disease progression.

The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.

Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.

Layered approach involves initially combining lifestyle interventions, self-management, and first-line pharmacotherapy

The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.

Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.

Canagliflozin decreases the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes, according to a new study.